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Abstract
Background: Formyl peptide receptors (FPRs) play pivotal roles in the regulation of 
innate immunity and host defense. The FPRs include three family members: FPR1, 
FPR2/ALX, and FPR3. The activation of FPR1 by its high‐affinity ligand, N‐formyl‐me‐
thionyl‐leucyl‐phenylalanine (fMLF) (a bacterial chemoattractant peptide), triggers 
intracellular signaling in immune cells such as neutrophils and exacerbates inflamma‐
tory responses to accelerate the clearance of microbial infection. Notably, fMLF has 
been demonstrated to induce intracellular calcium mobilization and chemotaxis in 
platelets that are known to play significant roles in the regulation of innate immunity 
and inflammatory responses. Despite a plethora of research focused on the roles of 
FPR1 and its ligands such as fMLF on the modulation of immune responses, their 
impact on the regulation of hemostasis and thrombosis remains unexplored.
Objective: To determine the effects of fMLF on the modulation of platelet reactivity, 
hemostasis, and thrombus formation.
Methods: Selective inhibitors for FPR1 and Fpr1‐deficient mice were used to determine 
the effects of fMLF and FPR1 on platelets using various platelet functional assays.
Results: N‐formyl‐methionyl‐leucyl‐phenylalanine primes platelet activation through 
inducing distinctive functions and enhances thrombus formation under arterial flow 
conditions. Moreover, FPR1 regulates normal platelet function as its deficiency in 
mouse or blockade in human platelets using a pharmacological inhibitor resulted in 
diminished agonist‐induced platelet activation.
Conclusion: Since FPR1 plays critical roles in numerous disease conditions, its influ‐
ence on the modulation of platelet activation and thrombus formation may provide 
insights into the mechanisms that control platelet‐mediated complications under di‐
verse pathological settings.
K E Y W O R D S
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1  | INTRODUC TION
Platelets are small circulating blood cells that play indispensable 
roles in the regulation of hemostasis to prevent excessive bleed‐
ing upon vascular injury. However, their unwarranted activation 
under pathological conditions leads to the formation of blood clots 
(thrombi) within the circulation.1 This results in reduced/retarded 
blood supply to vital organs including the heart and brain, which 
leads to heart attacks or strokes, respectively.2 Moreover, platelet 
activation during microbial infection results in their aggregation, 
thrombus formation in the microvasculature, and, in later stages, 
sequestration of platelets in organs such as the lungs, instigat‐
ing thrombocytopenia and bleeding complications.3 In addition 
to their prominent roles in hemostasis and thrombosis, platelets 
play a crucial role in the regulation of innate immunity, inflamma‐
tory responses, and clearance of microbial infection.4‒6 Platelets 
contain a broad spectrum of receptors that induce inflammatory 
responses during microbial infection and other pathological condi‐
tions. In addition, platelets secrete various inflammatory and im‐
munomodulatory molecules from their granules upon activation. 
They also possess antimicrobial proteins including thrombocidins, 
cathelicidins, and human β‐defensins that trigger direct microbicidal 
activities.4 Furthermore, platelets can directly bind and internalize 
invading microbes.7 The presence of major inflammatory molecules 
such as formyl peptide receptors (FPRs) and toll‐like receptors facil‐
itates platelets to recognize a diverse array of endogenous damage‐
associated molecular patterns and exogenous pathogen‐associated 
molecular patterns. Collectively, these properties render platelets 
effector and sentinel cells in primary host defense against invading 
pathogenic microbes.7,8
The FPRs belong to a family of G protein‐coupled receptors 
and are predominantly expressed in immune cells, where they play 
a prominent role in the regulation of inflammatory responses and 
host defense. In humans, three FPR family members have been 
identified: FPR1, FPR2/ALX, and FPR3.9 Although they were orig‐
inally identified by their capability to recognize N‐formyl peptides 
produced from bacteria or mitochondria of damaged cells, FPRs 
can bind a wide variety of structurally and functionally diverse li‐
gands. These include bacterial and mitochondrial formyl peptides, 
nonformylated peptides/proteins, and small lipid molecules.10 While 
FPR1 binds to bacterial‐derived N‐formyl peptides with high affinity, 
FPR2/ALX largely binds to mitochondrial formyl peptides.9,11 The li‐
gation of N‐formyl peptides to FPRs in immune cells triggers a range 
of signaling cascades resulting in numerous biological activities. For 
example, the stimulation of FPR1 by fMLF in neutrophils induces de‐
granulation, chemotaxis, production of superoxide anions, calcium 
mobilization, cytokine release, and expression of various surface 
markers.12,13 During microbial infection, invading bacteria release N‐
formyl peptides that facilitate the recruitment of immune cells to the 
site of infection and accelerate the clearance of microbial infection 
and repair of tissue damage.14
Czapiga et al15 reported the presence of FPR1 in platelets and its 
ability to induce chemotactic and migratory responses upon ligation 
with N‐formyl peptides, which emphasize a crucial role for FPR1 in 
platelet‐mediated immune responses. Notably, bacterial or synthetic 
fMLF has been shown to act as a potent chemotactic agent through 
FPR1 in platelets. Despite numerous reports on the immune func‐
tions of FPR1, its impact upon ligation with fMLF on the modulation 
of hemostasis and thrombosis remains uncharacterized. Recently, 
we have reported the presence of FPR2/ALX in human platelets and 
its significance in the regulation of LL37‐induced platelet activation 
and thrombus formation.16 Here, we report the ability of fMLF to 
prime platelets and augment thrombus formation, and the signifi‐
cance of FPR1 in the regulation of platelet function in the presence 
and absence of fMLF.
2  | METHODS
2.1 | Preparation of human platelet‐rich plasma and 
isolated platelets
The University of Reading Research Ethics Committee approved 
all the experimental procedures using human blood from healthy 
volunteers. The blood samples were collected from healthy, aspirin‐
free volunteers after obtaining written informed consent. The blood 
was collected into VACUETTE blood collection tubes containing 
3.2% (w/v) sodium citrate. The blood samples were then centrifuged 
at 102 g for 20 minutes at room temperature to obtain platelet‐rich 
plasma (PRP). The PRP was rested at 30°C for 30 minutes prior to 
use. For the preparation of isolated platelets, the blood was mixed 
with ACD [2.5% (w/v) sodium citrate, 2% (w/v) D‐glucose, and 1.5% 
(w/v) citric acid] at 1 (ACD): 9 (blood) ratio and centrifuged at 102 g 
for 20 minutes. The PRP was collected, mixed with appropriate vol‐
ume of ACD and prostaglandin I2 (PGI2), and centrifuged at 1413 g 
for 10 minutes at room temperature. The resultant platelet pellet 
was resuspended in modified Tyrodes‐HEPES buffer (134 mmol/L 
NaCl, 2.9 mmol/L KCl, 0.34 mmol/L Na2HPO4.12H2O, 12 mmol/L 
NaHCO3, 20 mmol/L HEPES, and 1 mmol/L MgCl2, pH 7.3) with ap‐
propriate volume of ACD and PGI2 and centrifuged once again at 
1413 g for 10 minutes at room temperature. The resultant platelet 
Essentials
• The role of formyl peptide receptor 1 (FPR1) and its li‐
gand, fMLF, in the regulation of platelet function, hemo‐
stasis, and thrombosis is largely unknown.
• Fpr1‐deficient mice and selective inhibitors for FPR1 
were used to investigate the function of fMLF and FPR1 
in platelets.
• N‐formyl‐methionyl‐leucyl‐phenylalanine primes plate‐
let activation and augments thrombus formation, mainly 
through FPR1 in platelets.
• Formyl peptide receptor 1 plays a pivotal role in the 
regulation of platelet function.
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pellet was resuspended to a final density of 4 × 108 cells/mL in modi‐
fied Tyrode's‐HEPES buffer and allowed to rest for 30 minutes at 
30°C prior to use.
2.2 | Mouse blood collection and platelet 
preparation
The mouse strains of Fpr1−/−17 and Fpr2/3−/−18 on a C57BL/6 back‐
ground obtained from William Harvey Research Institute, London, 
UK, and wild‐type C57BL/6 mice from Envigo, UK, were used in 
this study. The mice were sacrificed with CO2 and the blood was 
directly collected by cardiac puncture into a syringe containing 
3.2% (w/v) sodium citrate at 1 (citrate):9 (blood) ratio. The blood 
was then centrifuged at 203 g for 8 minutes at room temperature 
and the PRP was collected. The remaining blood was resuspended 
in 500 μL of modified Tyrode's‐HEPES buffer and centrifuged 
once again at 203 g for 5 minutes. The resultant PRP with PGI2 
then centrifuged at 1028 g for 5 minutes. The resultant platelet 
pellet was resuspended in modified Tyrode's‐HEPES buffer at a 
density of 2 × 108 cells/mL and rested for 30 minutes at 30°C 
prior to use.
2.3 | In vitro thrombus formation assay
The in vitro thrombus formation assay under arterial flow conditions 
was performed as described previously.19,20 Briefly, human DiOC6‐
labeled (Sigma Aldrich) human whole blood was preincubated with a 
vehicle, MLF or fMLF (5 μmol/L) or cyclosporin H (CsH) (10 μmol/L), 
for 10 minutes before perfusion over collagen (Nycomed) (400 μg/
mL)‐coated Vena8™ Biochips (Cellix Ltd) at a shear rate of 20 
dynes/cm2. Z‐stack fluorescence images of thrombi were obtained 
every 30 s for up to 10 minutes using a Nikon eclipse (TE2000‐U) 
microscope (Nikon Instruments). The fluorescence intensity was 
calculated by analyzing the data using ImageJ software (National 
Institutes of Health).
2.4 | Platelet adhesion assay
Platelet adhesion was measured by detecting the level of acid phos‐
phatase in immobilized platelet lysates. One hundred microliters of col‐
lagen (10 μg/mL in 0.01 M acetic acid) were added to 96‐well plates 
and incubated overnight at 4°C. The unbound collagen was discarded, 
and the wells were blocked with 175 μL of 5% (w/v) bovine serum al‐
bumin in modified Tyrode's‐HEPES for 1 h. Plates were then washed 
three times with 175 μL per well of 0.1% bovine serum albumin in modi‐
fiedTyrode's‐HEPES buffer. Platelets (1 × 108 cells/mL, 50 μL per well) 
were then added to wells and incubated at room temperature for 1 h. 
Nonadhered platelets were discarded, and the wells were washed three 
times with modified Tyrode's‐HEPES buffer. One hundred and fifty mi‐
croliters of citrate lysis buffer (3.53 mmol/L p‐nitrophenyl phosphate, 
71.4 mmol/L trisodium citrate, 28.55 mmol/L citric acid, 0.1% [v/v] 
Triton X‐100; pH 5.4) were added and the plate was incubated for 1 h 
at room temperature. The reaction was stopped by adding 2 M NaOH 
and the absorbance was measured at 405 nm using a Fluostar Optima 
spectrofluorimeter.
2.5 | Tail bleeding assay
The tail bleeding assay was performed as described previously.21 
The British Home Office has approved the experimental procedures. 
In brief, C57BL/6 (10‐12 weeks old; Envigo, UK) or Fpr1−/− mice were 
anesthetized using ketamine (80 mg/kg) and xylazine (5 mg/kg) ad‐
ministered via the intraperitoneal route and placed on a heated mat 
(37°C). The tail tip (3 mm) was dissected and immersed in sterile sa‐
line. The time to cessation of bleeding was measured and the assay 
was terminated at 20 minutes.
2.6 | Platelet aggregation assay
The platelet aggregation assays were performed by optical ag‐
gregometry using a two‐channel platelet aggregometer (Chrono‐
Log). Human isolated platelets or PRP (270 μL) were added into a 
siliconized cuvette and prewarmed at 37°C for 90 s. Upon addition 
of an agonist, the platelets were allowed to aggregate under con‐
tinuous stirring at 1200 rpm for 5 minutes at 37ºC and the level of 
aggregation was monitored. The platelets were pretreated with dif‐
ferent concentrations of fMLF (1, 5, 10, and 20 μmol/L) for 5 minutes 
before the addition of CRP‐XL (0.25 μg/mL), collagen (0.5 μg/mL), or 
thrombin (0.01 U/mL) and the level of aggregation was monitored. 
Data were analyzed by calculating the percentage of maximum 
platelet aggregation obtained at 5 minutes.
2.7 | Adenosine triphosphate secretion assay
To assess the level of dense granule secretion in platelets, adenosine 
triphosphate (ATP) secretion was measured using a luciferin–lucif‐
erase luminescence substrate (Chrono‐Log) by lumiaggregometry 
(Chrono‐log). The level of ATP released from platelets upon stimula‐
tion with a platelet agonist, CRP‐XL (0.25 μg/mL), in the presence 
and absence of different concentrations of Boc‐MLF was measured 
by observing the level of luminescence released.
2.8 | Statistical analysis
The data obtained in this study are represented as mean ± SEM. 
The statistical significance was analyzed using two‐tailed unpaired 
Student t test for two‐sample comparisons for the data obtained from 
the flow cytometric assay for FPR1 expression and platelet recep‐
tor characterization and cyclic adenosine monophosphate (cAMP) 
assay. For multiple comparisons such as for data obtained from in 
vitro thrombus formation, fMLF binding, ATP release, platelet ag‐
gregation, and activation, the statistical significance was established 
using 1‐way or 2‐way ANOVA followed by Bonferroni's correction. 
Data obtained from the tail bleeding assay were analyzed using a 
nonparametric Mann‐Whitney test. All statistical analyses were per‐
formed using Graphpad Prism 7 software (GraphPad Software Inc.).
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3  | RESULTS
3.1 | Platelets express FPR1
Recently, we have reported the presence of FPR2/ALX in human and 
its orthologue, Fpr2/3 in human platelets.16 Similarly, the expression 
of FPR1 in human platelets at protein level, and in megakaryocytes 
at transcript level, has been previously reported.15 Furthermore, 
the presence of FPR1 transcripts in human and mouse platelets was 
demonstrated.22 In line with these findings, here we confirmed the 
presence of FPR1 on the surface of human isolated platelets by flow 
cytometry and in isolated platelet lysates using immunoblot analy‐
sis. Notably, the activation of platelets using 1 μg/mL cross‐linked 
collagen‐related peptide (CRP‐XL) increased the level of FPR1 on 
the surface as determined by flow cytometry (Figure 1AI), while the 
level of proteins identified by immunoblots remained unchanged 
(Figure 1AII). These data confirm the presence of FPR1 in platelets, 
possibly in granules or the open canalicular system or both, and their 
increase on the surface upon activation similar to FPR2/ALX.16
3.2 | N‐formyl‐methionyl‐leucyl‐phenylalanine 
selectively binds to FPR1 on the platelet surface
A fluorescently‐labeled fMLF was used to investigate its binding 
to FPR1 on the surface of platelets by flow cytometry. To ascer‐
tain the selective binding of fMLF to FPR1, platelets obtained from 
Fpr1−/− and Fpr2/3−/− (an orthologue of human FPR2/ALX) mice 
along with their controls were used in this assay. The absence 
of Fpr1 in platelets obtained from Fpr1−/− mice was confirmed by 
immunoblot analysis (Figure 1BI). The level of Fpr1 identified in 
Fpr2/3−/− mouse platelets was found to be same as the controls. 
Notably, the absence of Fpr2/3 protein in platelets obtained 
from Fpr2/3−/− mice was confirmed previously.16 The binding of 
FITC‐fMLF (5 μmol/L) was significantly reduced in Fpr1−/− mouse 
isolated platelets compared to the control and Fpr2/3−/− mouse 
platelets (Figure 1BII). These data confirm the selective binding of 
fMLF to Fpr1 in mouse platelets.
3.3 | N‐formyl‐methionyl‐leucyl‐phenylalanine 
stimulates platelet activation
To determine whether fMLF is able to stimulate platelet activation 
upon binding to FPR1, a range of platelet functional assays were 
performed. Platelet activation triggers inside‐out signaling to inte‐
grin αIIbβ3 on the platelet surface and converts it to a high‐affinity 
state to allow fibrinogen binding and subsequent platelet aggrega‐
tion.23 To examine whether fMLF influences the inside‐out signal‐
ing to integrin αIIbβ3 in platelets, the level of fibrinogen binding 
on the platelet surface was measured as a marker for inside‐out 
signaling to integrin αIIbβ3. Indeed, fMLF has increased the level 
of fibrinogen binding in human isolated platelets in a concentra‐
tion‐dependent manner (Figure 1CI). A minimum concentration 
of 0.5 μmol/L fMLF has shown significant increase in fibrinogen 
binding compared to the resting platelets. Similarly, the level of P‐
selectin exposure on the platelet surface was measured as a marker 
for α‐granule secretion by flow cytometry. The results indicate that 
fMLF has induced α‐granule secretion in human isolated platelets 
in a concentration‐dependent manner (Figure 1CII). Similar to the 
isolated platelets, fMLF has increased the level of fibrinogen bind‐
ing and P‐selectin exposure in human platelets when PRP was used 
in a concentration‐dependent manner (Figure 1D). In addition, fMLF 
has increased the level of platelet adhesion to immobilized collagen 
under static conditions (Figure 2A). Together, these data confirm 
that the fMLF significantly primes platelet activation and adhesion.
3.4 | N‐formyl‐methionyl‐leucyl‐phenylalanine 
augments thrombus formation
Microbial infection and various inflammatory diseases including 
sepsis are associated with the risk of disseminated intravascular 
coagulation or thrombosis in the microvasculature.24 To investi‐
gate whether fMLF has a direct impact on thrombosis, its effect on 
thrombus formation under arterial flow conditions was analyzed. 
Human DiOC6‐labeled whole blood was preincubated with a control 
(nonformylated peptide, MLF) or fMLF (5 μM) for 10 minutes prior to 
perfusion over collagen‐coated Vena8™ biochips. Thrombus forma‐
tion was monitored for 10 minutes by acquiring fluorescent images 
at every 30 s . Indeed, fMLF has increased the mean fluorescence 
intensity of thrombi by approximately 60% compared to the con‐
trols (Figure 2B). These data demonstrate the direct impact of fMLF 
on augmenting the thrombus formation under arterial flow condi‐
tions in human whole blood. The effect of fMLF on other blood cells, 
mainly leukocytes, and their subsequent influence on thrombus for‐
mation cannot be ruled out under these circumstances.
3.5 | Agonist‐induced platelet aggregation is 
amplified by fMLF
Following the determination of the effects of fMLF on thrombus for‐
mation and platelet activation, aggregation assays were performed 
to establish its effects on isolated platelets. Human isolated platelets 
were incubated with various concentrations of fMLF (1, 5, 10, and 
20 μmol/L) prior to stimulation with subthreshold concentrations 
of different platelet agonists such as CRP‐XL (0.25 μg/mL), collagen 
(0.5 μg/mL), and thrombin (0.01 U/mL), and the level of aggrega‐
tion was monitored for 5 minutes by optical aggregometry. Notably, 
fMLF has failed to induce a noticeable platelet aggregation on its own 
(Figure 2C) although its preincubation with platelets markedly en‐
hanced agonist‐induced platelet aggregation. Maximum aggregation 
(100%) was obtained in human isolated platelets that were treated with 
20 μmol/L fMLF and 0.25 μg/mL CRP‐XL for 5 minutes (Figure 2C). 
Similar results were obtained with collagen‐induced (Figure 2D) and 
thrombin‐induced (Figure 2E) platelet aggregation. These data confirm 
the ability of fMLF to prime platelets and amplify their aggregation 
upon stimulation with different agonists although it was unable to ag‐
gregate platelets on its own under the current settings.
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F I G U R E  1   Expression of FPR1 in platelets and the impact of fMLF on platelet activation. A, the expression of FPR1 on the surface 
of resting or 1 μg/mL CRP‐XL‐ activated human isolated platelets was analyzed using FPR1‐selective and fluorescent‐labeled secondary 
antibodies by flow cytometry (AI). Data represent mean ± SEM (n = 8). Similarly, the presence of FPR1 in human isolated platelet lysates was 
confirmed by immunoblot analysis using selective antibodies (AII). B, the absence of Fpr1 was confirmed in isolated platelet lysates obtained 
from Fpr1−/− in comparison to the control and Fpr2/3−/− mice by immunoblot analysis using selective antibodies (BI). Isolated platelets 
obtained from control, Fpr1−/−, and Fpr2/3−/− mice were preincubated with 10 μmol/L FITC‐conjugated fMLF and their level of binding to the 
platelet surface was measured by flow cytometry (BII). Data represent mean ± SEM (n = 5). C, different concentrations of fMLF were used 
to determine their impact on platelet activation in human isolated platelets by quantifying the level of fibrinogen binding (CI) and P‐selectin 
exposure (CII) using flow cytometry. Data represent mean ± SEM (n = 10). D, different concentrations of fMLF were used to determine their 
effects on platelet activation in human platelet‐rich plasma (PRP) by quantifying the level of fibrinogen binding (DI) and P‐selectin exposure 
(DII) using flow cytometry. Data represent mean ± SEM (n = 10). The blots shown are representative of three separate experiments. Protein 
14‐3‐3ζ was detected as a loading control in the immunoblots. The statistical significance was calculated by 1‐way ANOVA followed by 
Bonferroni's correction in most of the experiments except the data shown in panel A, which were analyzed by 2‐tailed unpaired Student t 
test (*P < 0.01, **P < 0.001, and ***P < 0.0001). FITC, fluorescently labeled; fMLF, N‐formyl‐methionyl‐leucyl‐phenylalanine; FPR1, N‐formyl 
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3.6 | N‐formyl‐methionyl‐leucyl‐phenylalanine 
selectively acts through FPR1 in platelets
A large number of studies indicate that fMLF binds primarily to FPR1 
and exerts its effects in immune cells.25‒27 The functional depend‐
ence of fMLF on FPR1 in platelets was determined using a phar‐
macological inhibitor for FPR1, Boc‐MLF in human platelets, and 
platelets obtained from Fpr1−/− mice through measuring the levels 
of fibrinogen binding and P‐selectin exposure by flow cytometry. 
Similar to human platelets, fMLF increased the level of fibrinogen 
binding [Figure 3AI (isolated platelets) and AII (whole blood)] and 
P‐selectin exposure [Figure 3BI (isolated platelets) and BII (whole 
blood)] on platelets obtained from control mice. However, the level 
of platelet activation by fMLF was significantly reduced in Fpr1−/− 
mouse platelets, which demonstrates its functional dependence 
on FPR1. Here, the impact of leukocytes upon binding to fMLF on 
platelet activation cannot be ruled out in whole blood obtained 
from control mice. Notably, the characterization of platelets ob‐
tained from Fpr1−/− mice failed to display any defects in the size and 
number of platelets or the levels of major platelet receptors such as 
GPVI (Figure S1i), GPIbα (Figure S1ii), αIIbβ3 (Figure S1iii), and ɑ2β1 
(Figure S1iv) in comparison to the control mouse platelets. To estab‐
lish the functional dependence of fMLF on FPR1 in human platelets, 
similar assays were performed in the presence or absence of Boc‐
MLF. The preincubation of human isolated platelets with different 
concentrations of Boc‐MLF diminished fMLF (5 μmol/L)‐induced 
platelet activation as measured by the levels of fibrinogen binding 
(Figure 3CI) and P‐selectin exposure (Figure 3CII). To determine 
whether fMLF also acts through FPR2/ALX, the platelet activation 
was measured in the presence or absence of an FPR2/ALX‐selec‐
tive inhibitor, WRW4. The preincubation of human isolated plate‐
lets with different concentrations of WRW4 did not affect the level 
of fMLF‐induced (5 μmol/L) platelet activation as measured by the 
levels of fibrinogen binding (Figure 3DI) and P‐selectin exposure 
(Figure 3DII). Together, these data emphasize the involvement of 
FPR1 in the regulation of fMLF‐mediated effects in platelets.
3.7 | Inhibition of FPR1 reduces the agonist‐induced 
platelet activation
In order to study the importance of FPR1 in the regulation of nor‐
mal platelet activation, further experiments were performed using 
human isolated platelets in the presence or absence of Boc‐MLF. 
The CRP‐XL (0.25 μg/mL)‐induced platelet aggregation was sig‐
nificantly reduced in the presence of different concentrations of 
Boc‐MLF (1, 5, 10, and 20 μmol/L). For example, the addition of 
Boc‐MLF (20 μmol/L) reduced the platelet aggregation by around 
89% (Figure 4A). Similar results were obtained with ADP‐induced 
platelet aggregation, wherein Boc‐MLF (20 μmol/L) reduced ag‐
gregation by approximately 82% (Figure 4B). Moreover, CRP‐XL 
(0.25 μg/mL)‐induced dense granule secretion as evidenced by 
the ATP release was significantly reduced by Boc‐MLF (Figure 4C). 
Similarly, to determine whether FPR1 has any influence on the 
outside‐in signaling triggered by integrin αIIbβ3, platelet spread‐
ing assay was performed on fibrinogen‐coated glass surfaces and 
analyzed using confocal microscopy. The preincubation of platelets 
with Boc‐MLF (1, 5, 10, and 20 μmol/L) significantly decreased the 
number of adhered (Figure 5AI) and spread (Figure 5AII) platelets, 
and the relative surface area of spreading on fibrinogen‐coated sur‐
faces (Figure 5AIII) indicating a role for FPR1 in the modulation of 
integrin αIIbβ3‐mediated outside‐in signaling in platelets. In order 
to corroborate the involvement of FPR1 in the regulation of platelet 
function, CsH, an inverse agonist for FPR1, was employed. The CsH 
inhibited CRP‐XL (0.5 μg/mL)‐induced human isolated platelet acti‐
vation as measured by the levels of fibrinogen binding (Figure 5BI) 
and P‐selectin exposure (Figure 5BII). Furthermore, CsH decreased 
the mean fluorescence intensity of thrombi in human whole blood 
under arterial flow conditions by approximately 60% compared to 
the controls (Figure 5C). These results highlight the prominent roles 
of FPR1 in the regulation of normal platelet function.
3.8 | Deletion of FPR1 affects mouse 
platelet activation
To examine further the impact of FPR1 in platelets, the whole blood 
obtained from control and Fpr1−/− mice was used to assess the platelet 
activation upon stimulation with a range of conventional platelet ago‐
nists by measuring the levels of fibrinogen binding and P‐selectin expo‐
sure using flow cytometry. Similar to the results obtained with human 
platelets (Figure 4), the level of (I) fibrinogen binding and (II) P‐selec‐
tin exposure in platelets obtained from Fpr1−/− mice upon stimulation 
with CRP‐XL (Figure 6A), ADP (Figure 6B), AY‐NH2 (a PAR4 agonist) 
(Figure 6C), and U46619, an analog of TXA2 (Figure 6D) was largely re‐
duced compared to their controls. To determine the influence of FPR1 
on the modulation of hemostasis, tail bleeding assay was performed 
in control and Fpr1‐deficient mice. A mean bleeding time of 429 s was 
observed in the control group; however, Fpr1−/− mice had a significantly 
increased bleeding time to a mean of 1128 s (Figure 6E). These data 
indicate the importance of FPR1 in the modulation of platelet function 
and the maintenance of hemostasis under physiological conditions. 
Moreover, these results are similar to the data that were reported for 
Fpr2/3−/− mice16 emphasizing the physiological significance of FPRs in 
the modulation of platelet function and hemostasis.
3.9 | The inhibition or deletion of FPR1 
increases the level of cyclic AMP
Cyclic AMP (cAMP) is a potent inhibitor of platelet function and 
its level is generally reduced upon platelet activation. Stimulants 
of cAMP generation are known to inhibit platelet activation.28 
The FPRs are Gi protein‐coupled receptors,
29 which are known 
to inhibit adenylate cyclase and thus, lead to a reduction in cAMP 
levels. Therefore, the deletion of genes for Gi‐coupled recep‐
tors in mice generally increases the basal levels of cAMP in target 
cells.30,31 To investigate whether the effects of FPR1 in platelets 
are driven through cAMP‐dependent signaling, the level of cAMP 
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was quantified in platelets using a cAMP assay kit. The inhibition 
of FPR1 in human isolated platelets with Boc‐MLF (20 μmol/L) 
significantly elevated the level of cAMP compared to the controls 
(Figure 6FI). Similarly, Fpr1−/− mouse isolated platelets exhibited el‐
evated basal levels of cAMP compared to the control mouse plate‐
lets at resting conditions (Figure 6FII). These data illustrate that the 
level of cAMP may play a key role in the regulation of FPR1‐medi‐
ated function in platelets.
4  | DISCUSSION
N‐formyl peptides are released from bacteria or mitochondria of 
damaged cells.32,33 They have been demonstrated to play substantial 
roles in the initiation of chemotaxis and subsequent inflammatory 
responses in immune cells including monocytes, mast cells, eo‐
sinophils, and neutrophils via FPRs.9 Despite their ability to medi‐
ate innate immune responses, they have been associated with the 
pathogenesis of microbial infection and inflammatory diseases. 
Notably, E coli‐derived fMLF34 has been implicated in bacterial cys‐
titis,35 pneumococcal pneumonia,36 inflammatory bowel disease,37 
pouchitis, colitis38 and juvenile peridontitis.39 It has been shown that 
inhalation or injection of fMLF can cause bronchial inflammation40 
and induce rapid neutropenia, thereby increasing susceptibility to 
infection.41 The plasma levels of fMLF were increased in these con‐
ditions, and also in high‐fat‐diet‐treated mice due to altered microbi‐
ome where it impaired the glucose tolerance and insulin secretion.42 
Many of these infectious and inflammatory conditions are associ‐
ated with a risk for thrombosis and other platelet‐mediated compli‐
cations.43‒45 The concentrations of fMLF in the intestinal milieu have 
F I G U R E  3   The effects of fMLF on platelet activation are largely mediated via FPR1. The platelet activation upon stimulation with 
various concentrations of fMLF was quantified by measuring A, the level of fibrinogen binding using FITC‐conjugated fibrinogen antibodies 
and P‐selectin exposure (B), using PECy5‐conjugated P‐selectin antibodies in isolated platelets (I) or whole blood (II) obtained from control 
and Fpr1−/− mice by flow cytometry. Data represent mean ± SEM (n = 6 for isolated platelets and n = 5 for whole blood). C, human isolated 
platelets were stimulated with fMLF (5 μmol/L) in the presence or absence of different concentrations of Boc‐MLF (1, 5, 10, and 20 μmol/L), 
and the levels of fibrinogen binding (CI) and P‐selectin exposure (CII) were analyzed by flow cytometry. Data represent mean ± SEM (n = 5). 
D, similarly, human isolated platelets were stimulated with fMLF (5 μmol/L) in the presence or absence of various concentrations of WRW4 
(1, 5, 10, and 20 μmol/L), and the levels of fibrinogen binding (DI) and P‐selectin exposure (DII) were analyzed by flow cytometry. Data 
represent mean ± SEM (n = 5). *Represents the significant difference between the various concentrations of fMLF within the Fpr1+/+ group. 
#Represents the significant difference between Fpr1+/+ and Fpr1−/− groups. The statistical significance was calculated by 2‐way ANOVA 
followed by Bonferroni's correction in most of the experiments except the data shown in panel C and D, which were analyzed by 1‐way 
ANOVA followed by Bonferroni's correction (*P < 0.01. **P <0.001, and ***P < 0.0001). FITC, Fluorescein isothiocyanate; fMLF, N‐formyl‐
methionyl‐leucyl‐phenylalanine; FPR1, N‐formyl peptide receptor‐1
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related peptide (CRP‐XL)‐induced, , D, collagen‐induced, or E, thrombin‐induced platelet activation were measured using isolated human 
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Bonferroni's correction in most of the experiments except the data shown in panels B, which were analyzed by 2‐tailed unpaired Student t test 
(*P <0.01, **P <0.001, and ***P <0.0001). fMLF, N‐formyl‐methionyl‐leucyl‐phenylalanine; MLF, methionyl‐leucyl‐phenylalanine
1128  |     SALAMAH et AL.
been reported to be at least in micromolar ranges.46 In this study, 
we demonstrate that fMLF is able to prime platelets and augment 
thrombus formation in micromolar concentrations. Therefore, the 
increased levels of fMLF under the aforementioned pathological 
conditions may lead to platelet activation and contribute to throm‐
botic complications.
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The activation of platelets facilitates their adhesion to leukocytes 
and leads to the formation of platelet‐leukocyte aggregates (PLAs).47 
P‐selectin on the surface of activated platelets drives the formation 
of PLAs via binding to P‐selectin glycoprotein ligand‐1 on the sur‐
face of leukocytes.48 In addition, the fibrinogen binding to integrin 
αIIbβ3 in platelets and Mac‐1 in neutrophils was suggested to play an 
F I G U R E  5   Blockade of FPR1 using a pharmacological inhibitor reduces platelet spreading, activation and thrombus formation. A, platelet 
adhesion and spreading on fibrinogen‐coated glass surface was analyzed in the absence or presence of Boc‐MLF (1, 5, 10, and 20 μmol/L) 
by confocal microscopy (60× magnification; scale bar ‐ 10 μm). The number of adhered (AI) and spread platelets (AII) and the relative 
surface area of spread platelets (AIII) were determined by analyzing the images using ImageJ. Ten random fields of view were recorded 
for each sample. Data represent mean ± SEM (n = 3). B, the levels of fibrinogen binding (BI) and P‐selectin exposure (BII) were analyzed in 
human platelet‐rich plasma (PRP) by flow cytometry upon stimulation with CRP‐XL (0.5 μg/mL), in the presence and absence of different 
concentrations of CsH (1, 5, 10, 20, and 30 μmol/L). Data represent mean ± SEM (n = 3). C, the impact of CsH on the modulation of thrombus 
formation was analyzed using human DiOC6‐labeled whole blood that was preincubated with a vehicle control or 10 μmol/L CsH for 10 min 
prior to perfusion over collagen‐coated (400 μg/mL) Vena8™ Biochips. Images shown are representative of three separate experiments 
(10× magnification; scale bar ‐ 10 μm). Data represent mean ± SEM (n = 3). P values shown are as calculated by 1‐way ANOVA followed 
by Bonferroni's correction except for data shown in C, which were analyzed by 2‐tailed unpaired Student t test, respectively. (*P < 0.01, 
**P < 0.001, and ***P < 0.0001) CRP‐XL, cross‐linked collagen‐related peptide; CsH, cyclosporin H; MLF, methionyl‐leucyl‐phenylalanine
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F I G U R E  4   Blockade of FPR1 using a pharmacological inhibitor reduces agonist‐induced platelet aggregation. The effect of different 
concentrations of Boc‐MLF on CRP‐XL (0.25 μg/mL)‐induced aggregation using human isolated platelets (A) or ADP (2 μmol/L)‐induced 
aggregation using human platelet‐rich plasma (B) was analyzed by optical aggregometry. The level of aggregation obtained with the vehicle 
control was taken as 100% to calculate the extent of inhibition with Boc‐MLF‐treated samples. Data represent mean ± SEM (n = 3). Similarly, 
the level of ATP secretion in human isolated platelets upon activation with CRP‐XL (0.25 μg/mL) in the presence and absence of different 
concentrations of Boc‐MLF was measured by lumiaggregometry (C). Data represent mean ± SEM (n = 3). P values shown are as calculated by 
1‐way ANOVA followed by Bonferroni's correction. (*P < 0.01, **P < 0.001, and ***P <0.0001). ATP, adenosine triphosphate; CRP‐XL, cross‐
linked collagen‐related peptide; FPR1, N‐formyl peptide receptor‐1; MLF, methionyl‐leucyl‐phenylalanine
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important role in the formation of PLAs.49 The PLAs are known to 
amplify thrombotic and proinflammatory responses in diverse inflam‐
matory settings.50 Indeed, fMLF has been reported to induce PLA 
formation51 through fibrinogen binding in platelets and neutrophils.49 
Moreover, previous studies have reported the aggregation of plate‐
lets in response to fMLF‐induced neutrophil stimulation51‒53 through 
release of platelet‐activating factor54 and cathepsin G.55,56 In line 
with these, we demonstrate that fMLF has failed to induce aggrega‐
tion of isolated platelets although the pretreatment of platelets with 
fMLF augmented agonist‐induced aggregation. Furthermore, fMLF 
augmented thrombus formation under arterial flow conditions in 
whole blood. Given that fMLF is able to upregulate the expression of 
adhesion molecules57,58 and aggregate neutrophils,49,53 its effects on 
thrombus formation may be partly attributed to its interactions with 
leukocytes. Therefore, fMLF‐induced fibrinogen binding and P‐selec‐
tin exposure in platelets may directly trigger PLA formation as de‐
tailed previously.59 Although in this study the direct impact of fMLF 
on platelet‐mediated inflammatory responses was not analyzed, the 
role of fMLF cannot be excluded in such responses. Together, these 
data demonstrate a prominent priming role for fMLF in platelets, 
which may augment thrombotic and proinflammatory responses 
through interactions with leukocytes in pathological settings.
Formyl peptide receptor 1 is a chemoattractant receptor that 
is widely expressed in various cell types including neutrophils, 
macrophages, and platelets.15 Despite its well‐characterized role 
in the modulation of inflammatory responses, the role of FPR1 in 
the regulation of platelet function is poorly studied. Here, we re‐
port a crucial role for FPR1 on the regulation of platelet activation, 
hemostasis, and thrombosis. In line with a previous study,15 we 
confirm the presence of this receptor in human platelets by immu‐
noblot analysis, and its upregulation upon activation of platelets 
with an agonist. By using selective pharmacological inhibitor, Boc‐
MLF and an inverse agonist, cyclosporin H (CsH), the significance 
of FPR1 in the regulation of fMLF‐induced and agonist‐induced 
F I G U R E  6   Deletion of Fpr1 in mice reduces the agonists‐induced platelet activation and affects hemostasis. The levels of fibrinogen 
binding (I) and P‐selectin exposure (II) were analyzed in isolated platelets obtained from control or Fpr1−/− mice upon stimulation with 
various concentrations of agonists such as CRP‐XL (A), ADP (B), AY‐NH2 (C), or U46691 (D), by flow cytometry. Data represent mean ± SEM 
(n = 4). E, the impact of FPR1 on the modulation of hemostasis was analyzed by tail bleeding assay in control or Fpr1−/− mice. Data represent 
mean ± SEM (n = 8). F, the level of cAMP in human isolated platelets in the presence or absence of Boc‐MLF (I), and in control and Fpr1−/− 
mouse isolated platelets (II), was analyzed using a cAMP assay kit. *Represents the significant difference between the various concentrations 
of agonists within the Fpr1+/+ group. #Represents the significant difference between Fpr1+/+ and Fpr1−/− groups. Data represent mean ± SEM 
(n = 4). The statistical significance was calculated by 2‐way ANOVA followed by Bonferroni's correction in most of the experiments except 
for the data shown in panels E and F, which were calculated by non parametric Mann‐Whitney test, and 2‐tailed unpaired Student t test, 
respectively (*P <0.01, **P <0.001, and ***P <0.0001). ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate; CRP‐XL, cross‐
linked collagen‐related peptide; FPR1, N‐formyl peptide receptor‐1
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(such as CRP‐XL and ADP) platelet activation was established. The 
blockade of FPR1 resulted in reduced ATP release upon activa‐
tion with CRP‐XL, which not only affects secondary platelet ac‐
tivation but may also influence the modulation of inflammatory 
responses.60 Similarly, the inhibition of FPR1 impaired the ability 
of platelet spreading on fibrinogen, which is essential for throm‐
bosis and subsequent wound repair.61 The specificity of inhibitors 
to FPR1 may be limited by their ability to bind FPR2/ALX nonspe‐
cifically at higher concentrations. Therefore, the prominent role 
of FPR1 on the regulation of platelet activation was also corrob‐
orated using platelets obtained from Fpr1‐deficient mice, wherein 
the effects of fMLF and platelet agonists were largely diminished. 
The selective binding of fMLF to Fpr1 was confirmed using plate‐
lets obtained from Fpr1‐deficient mice. In addition, the hemostasis 
in Fpr1‐deficient mice was affected further emphasizing its signif‐
icance in the regulation of platelet function. Fpr1‐deficient mice 
displayed severe inflammation, higher mortality during pneumo‐
coccal meningitis,62 increased susceptibility to Listeria monocy-
togenes infection, and impaired antibacterial host defense.17 In 
addition, Fpr1‐deficient mice demonstrate major roles in sterile 
inflammation triggered by mitochondrial N‐formyl peptides as 
demonstrated by the attenuation of inflammation in response to 
sterile acute lung injury in these mice.64 In line with these studies, 
here we demonstrate the dysfunction of platelets and affected he‐
mostasis in Fpr1‐deficient mice, which may also substantiate the 
reduced inflammatory responses due to significant contribution of 
platelets in inflammation and innate immunity.
As a Gi protein‐coupled receptor, FPR1 triggers downstream 
signaling via various molecules such as phospholipase C, PI3K/AKT, 
and MAPK, and modulates calcium mobilization in neutrophils.13 
The ability of fMLF to induce calcium mobilization in platelets has 
been previously reported.15 Here, we report the impact of FPR1 on 
cAMP‐mediated signaling in platelets using Boc‐MLF and platelets 
obtained from Fpr1‐deficient mice. Indeed, the inhibition of FPR1 in 
human platelets or its deletion in mouse platelets resulted in ele‐
vated levels of cAMP, which is a potent inhibitor for platelet activa‐
tion. This confirmed the involvement of cAMP‐dependent signaling 
in the regulation of FPR1‐mediated effects in platelets.
Given the significance of FPRs and their ligands under various 
clinical settings, the therapeutic potential of these are being widely 
investigated. Notably, honokiol, a plant‐derived bioactive agent, 
has recently been demonstrated to reduce the proinflammatory re‐
sponses induced by fMLF in neutrophils through inhibiting FPR1.65 
Recently, we have reported the presence of FPR2/ALX in platelets, 
and its significance in the activation of platelets and thrombus for‐
mation upon ligation with an antimicrobial cathelicidin, LL37.16 In 
conclusion, similar to LL37, this study demonstrates a prominent role 
for fMLF for priming platelet activation and augmenting thrombus 
formation under arterial flow conditions. Using an FPR1 selective in‐
hibitor and Fpr1‐deficient mice, the functional dependence of fMLF 
on this receptor was established. Therefore, the priming effects 
of fMLF on platelets may significantly contribute to the develop‐
ment of thrombotic and proinflammatory diatheses in pathological 
settings where the level of fMLF is elevated. Hence, FPR1 may act 
as a potential therapeutic target and its ligands may provide a pow‐
erful platform to develop novel therapeutic agents in order to treat 
and prevent thrombotic and inflammatory complications in diverse 
pathophysiological settings.
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